Reference : Evaluation of Presumably Disease Causing SCN1A Variants in a Cohort of Common Epileps...
Scientific journals : Article
Life sciences : Genetics & genetic processes
http://hdl.handle.net/10993/26179
Evaluation of Presumably Disease Causing SCN1A Variants in a Cohort of Common Epilepsy Syndromes
English
Lal, Dennis []
Reinthaler, Eva []
Dejanovic []
May, Patrick mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Thiele, Holger []
Lehesjoki, Anna-Elina []
Schwarz, Guenter []
Riesch, Erik []
Ikram, Arfan []
van Duijn, Cornelia []
Uitterlinden, Andre []
Steinböck, Hannelore []
Gruber-Sedlmayr, Ursula []
Neophytou, Birgit []
Zara, Frederico []
Hahn, Andreas []
Genetic Commission of the Italian League against Epilepsy []
EuroEPINOMICS CoGIE Consortium []
Balling, Rudi mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Becker, Felicitas []
Weber, Yvonne []
Cilio, Maria Roberta []
Kunz, Wolfram []
Krause, Roland mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Zimprich, Fritz []
Lemke, Johannes R. []
Nürnberg, Peter []
Sander, Thomas []
Lerche, Holger []
Neubauer, Bernd []
18-Mar-2016
PLoS ONE
Public Library of Science
Yes (verified by ORBilu)
International
1932-6203
San Franscisco
CA
[en] Genetics ; Epilepsy ; SCN1A
[en] Objective

The SCN1A gene, coding for the voltage-gated Na+ channel alpha subunit NaV1.1, is the clinically most relevant epilepsy gene. With the advent of high-throughput next-generation sequencing, clinical laboratories are generating an ever-increasing catalogue of SCN1A variants. Variants are more likely to be classified as pathogenic if they have already been identified previously in a patient with epilepsy. Here, we critically re-evaluate the pathogenicity of this class of variants in a cohort of patients with common epilepsy syndromes and subsequently ask whether a significant fraction of benign variants have been misclassified as pathogenic.
Methods

We screened a discovery cohort of 448 patients with a broad range of common genetic epilepsies and 734 controls for previously reported SCN1A mutations that were assumed to be disease causing. We re-evaluated the evidence for pathogenicity of the identified variants using in silico predictions, segregation, original reports, available functional data and assessment of allele frequencies in healthy individuals as well as in a follow up cohort of 777 patients.
Results and Interpretation

We identified 8 known missense mutations, previously reported as pathogenic, in a total of 17 unrelated epilepsy patients (17/448; 3.80%). Our re-evaluation indicates that 7 out of these 8 variants (p.R27T; p.R28C; p.R542Q; p.R604H; p.T1250M; p.E1308D; p.R1928G; NP_001159435.1) are not pathogenic. Only the p.T1174S mutation may be considered as a genetic risk factor for epilepsy of small effect size based on the enrichment in patients (P = 6.60 x 10−4; OR = 0.32, fishers exact test), previous functional studies but incomplete penetrance. Thus, incorporation of previous studies in genetic counseling of SCN1A sequencing results is challenging and may produce incorrect conclusions.
Luxembourg Centre for Systems Biomedicine (LCSB): Bioinformatics Core (R. Schneider Group) ; Luxembourg Centre for Systems Biomedicine (LCSB): Experimental Neurobiology (Balling Group)
Researchers
http://hdl.handle.net/10993/26179
10.1371/journal.pone.0150426
http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0150426

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
journal.pone.0150426.PDFPublisher postprint265.45 kBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.